Table 1.

Description of the end-points used in paediatric rheumatology clinical trials 8,9

Criteria	Components	Definitions of end-points used
PedACR criteria for determining the magnitude of the treatment response in juvenile idiopathic arthritis	Core set measures: Physician's global assessment of disease activity (10 cm visual analog scale) Patient and/or parent global assessment of overall wellbeing Number of active joints Number of joints with limited range of movement Disability index [childhood health assessment questionnaire (CHAQ) score] Erythrocyte sedimentation rate	PedACR30 response is frequently used to assess treatment response in paediatric rheumatology clinical trials. A significant clinical response to treatment is defined as improvement of ≥30% in at least three of the six criteria, without worsening of ≥30% in no more than one criterion PedACR50, 70, 90 response is defined as improvement of ≥50, ≥70, ≥90% in at least three of the six criteria, Without worsening by ≥50, ≥70, ≥90% in no more than one criterion Disease flare can be defined using the PedACR criteria and is defined as three of the six core set variables worsening by ≥30%, with no more than one of the six improving by ≥30%
Inactive disease	No joints with active arthritis No fever, rash, serositis, splenomegaly or generalized lymphadenopathy attributable to juvenile idiopathic arthritis No active uveitis Normal erythrocyte sedimentation rate or C-reactive protein No disease activity according to the doctor's evaluation
Clinical remission	On medication – criteria for inactive disease met for 6 months on treatment Off medication – criteria for inactive disease met for 12 months off treatment

Abbreviation is as follows: PedACR, paediatric American College of Rheumatology criteria.